Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41467-018-03573-6
Title: Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression
Authors: Latonen, L
Afyounian, E
Jylhä, A
Nättinen, J
Aapola, U
Annala, M
Kivinummi, K.K
Tammela, T.T.L
Beuerman, R.W 
Uusitalo, H
Nykter, M
Visakorpi, T
Keywords: messenger RNA
microRNA
proteome
messenger RNA
microRNA
transcriptome
tumor protein
cancer
castration
citric acid
gene expression
genetic analysis
methylation
protein
proteomics
adult
aged
Article
cancer growth
castration resistant prostate cancer
citric acid cycle
controlled study
DNA methylation
gene dosage
gene expression level
genomics
human
human tissue
male
mass spectrometry
prostate cancer
prostate hypertrophy
proteogenomics
proteomics
transcriptomics
disease exacerbation
gene expression regulation
genetics
genome-wide association study
genomics
metabolism
middle aged
pathology
prostate
Aged
Citric Acid Cycle
Disease Progression
DNA Methylation
Gene Dosage
Gene Expression Regulation, Neoplastic
Genome-Wide Association Study
Genomics
Humans
Male
MicroRNAs
Middle Aged
Neoplasm Proteins
Prostate
Prostatic Hyperplasia
Prostatic Neoplasms, Castration-Resistant
RNA, Messenger
Transcriptome
Issue Date: 2018
Publisher: Nature Publishing Group
Citation: Latonen, L, Afyounian, E, Jylhä, A, Nättinen, J, Aapola, U, Annala, M, Kivinummi, K.K, Tammela, T.T.L, Beuerman, R.W, Uusitalo, H, Nykter, M, Visakorpi, T (2018). Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nature Communications 9 (1) : 1176. ScholarBank@NUS Repository. https://doi.org/10.1038/s41467-018-03573-6
Rights: Attribution 4.0 International
Abstract: To understand functional consequences of genetic and transcriptional aberrations in prostate cancer, the proteomic changes during disease formation and progression need to be revealed. Here we report high-throughput mass spectrometry on clinical tissue samples of benign prostatic hyperplasia (BPH), untreated primary prostate cancer (PC) and castration resistant prostate cancer (CRPC). Each sample group shows a distinct protein profile. By integrative analysis we show that, especially in CRPC, gene copy number, DNA methylation, and RNA expression levels do not reliably predict proteomic changes. Instead, we uncover previously unrecognized molecular and pathway events, for example, several miRNA target correlations present at protein but not at mRNA level. Notably, we identify two metabolic shifts in the citric acid cycle (TCA cycle) during prostate cancer development and progression. Our proteogenomic analysis uncovers robustness against genomic and transcriptomic aberrations during prostate cancer progression, and significantly extends understanding of prostate cancer disease mechanisms. © 2018 The Author(s).
Source Title: Nature Communications
URI: https://scholarbank.nus.edu.sg/handle/10635/178420
ISSN: 2041-1723
DOI: 10.1038/s41467-018-03573-6
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41467-018-03573-6.pdf1.74 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

40
checked on Nov 27, 2020

Page view(s)

10
checked on Dec 3, 2020

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons